Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

Pomalyst Is More Cost-effective Than Darzalex or Kyprolis for Heavily Treated Myeloma Patients, Study Reports

A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or refractory multiple myeloma (RRMM), a study shows. The research, published in Clinical Therapeutics, is titled “Cost-effectiveness of Pomalidomide, Carfilzomib, and ... Read more